ReviewLung2025
Roles of Pyruvate Kinase M2 in Pulmonary Diseases: What Do We Know So Far?
Review in Lung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Trained immunity in respiratory diseases: Mechanisms of action and intervention strategies.Chinese medical journal pulmonary and critical care medicine · 2026Review
- PKM2 Promotes Glycolysis in Alveolar Macrophages and Induces Inflammation in Bronchopulmonary Dysplasia.Inflammation · 2026Article
- Dual roles of amino acid metabolic reprogramming in chronic airway diseases and lung cancer: therapeutic opportunities and challenges.World journal of surgical oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pyruvate kinase M2 (PKM2) is a critical enzyme regulating cell metabolism and growth under different physiological conditions. In its metabolic role, PKM2 catalyzes the final and also a rate-limiting reaction in the glycolytic pathway, converting phosphoenolpyruvate (PEP) to pyruvate while phosphorylating adenosine diphosphate (ADP) to pyruvate and adenosine-triphosphate (ATP). Also, PKM2 has been reported to function as a protein kinase that regulates gene transcription and expression involved in cellular growth and survival. Current studies have focused on the glycolytic and non‑glycolytic functions of PKM2 in various tissues and organs. In this review, we summarize the in-depth role of PKM2 in the pathogenesis in pulmonary diseases including chronic obstructive pulmonary disease (COPD), asthma, pulmonary arterial hypertension (PAH), acute lung injury (ALI), pulmonary fibrosis, infectious lung disease and lung cancer. We also discuss its potential applications in disease diagnosis and therapies.
Indexed as
Identifiers
40464996What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.